Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides caloric supplementation and serves as a source of glucose for cellular metabolism. Sodium chloride provides electrolytes for maintenance of fluid and electrolyte balance.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Parenteral replenishment of fluid and calories in patients unable to take adequate oral intake,Correction of fluid and electrolyte imbalances,As a vehicle for intravenous drug administration
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion; typical adult dose is 1000-2000 m L per day, rate dependent on clinical condition and fluid status; maximum infusion rate usually 5 m L/kg/hour.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Dextrose has a plasma half-life of approximately 1-2 hours; sodium and chloride have half-lives that depend on renal function and hydration status, typically 6-12 hours for sodium. In clinical context, half-life is not typically used for fluid and electrolyte replacement.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Dextrose is metabolized via glycolysis and the citric acid cycle; sodium chloride is not metabolized.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Dextrose and sodium chloride are endogenous substances. Dextrose is metabolized to CO2 and water; excess is excreted renally as glucose. Sodium and chloride are primarily excreted renally, with minimal biliary/fecal elimination. Nearly 100% of infused sodium and chloride are eliminated renally under normal conditions.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Dextrose: negligible (<1%). Sodium: negligible. Chloride: negligible.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Dextrose: approximately 0.2 L/kg (extracellular fluid). Sodium: 0.2 L/kg (extracellular fluid). Chloride: 0.2 L/kg (extracellular fluid). These reflect distribution primarily in extracellular space.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100%.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
e GFR <30 m L/min: Use with caution; monitor fluid and electrolyte balance; adjust volume and rate based on renal function and urine output.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific adjustment required; use caution in severe hepatic impairment due to potential volume overload.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Weight-based: Initial dose 5-10 m L/kg, may repeat as needed; maintenance: 80-120 m L/kg/day for infants and 60-80 m L/kg/day for older children; adjust rate based on clinical response and glucose/electrolyte monitoring.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Start at lower end of adult dose; monitor for fluid overload, hyperglycemia, and electrolyte disturbances due to decreased renal function and cardiovascular reserve.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
None
None.
Risk of hyperglycemia, especially in patients with diabetes mellitus or impaired glucose tolerance,Risk of fluid overload, particularly in patients with cardiac or renal impairment,Electrolyte imbalances with prolonged use or rapid infusion,May cause phlebitis or extravasation at infusion site,Use with caution in patients with intracranial or intraspinal hemorrhage
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperglycemia (severe) or diabetic coma with hyperglycemia,Hypersensitivity to any component,Clinically significant hypernatremia or fluid overload,Patients with increased intracranial pressure
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No specific food interactions. However, due to dextrose content, patients with diabetes should monitor blood glucose closely. Avoid concurrent use with alcohol due to risk of hypoglycemia or hyperglycemia.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
First trimester: No evidence of teratogenicity from dextrose or sodium chloride at recommended doses. Second and third trimesters: Use is generally safe; however, administration of large volumes may cause electrolyte imbalances and fluid overload, potentially affecting fetal hydration status.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Both dextrose and sodium chloride are endogenous substances and are present in breast milk at concentrations similar to maternal plasma. M/P ratio: Not applicable; considered compatible with breastfeeding.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No dose adjustments required for standard maintenance fluids. However, pregnant patients may have increased volume of distribution and renal clearance; monitor for fluid and electrolyte balance, and adjust infusion rate accordingly to prevent overload.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Contains 10% dextrose (100 g/L) and 0.2% sodium chloride (34 m Eq/L Na+ and Cl-). Osmolality approximately 505 m Osm/L, p H ~4.0. Provides 340 kcal/L. Use with caution in patients with fluid overload, heart failure, or renal impairment. Monitor serum glucose, electrolytes, and fluid balance. Not for use as a sole source of nutrition; consider thiamine supplementation in chronic alcoholics to prevent Wernicke's encephalopathy. Do not administer with blood products through same IV line.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This solution provides sugar (dextrose) and salt (sodium chloride) to help maintain your body's fluid and energy balance.,Report any signs of allergic reaction, such as rash, itching, or difficulty breathing, during infusion.,Inform your healthcare provider if you have diabetes, high blood pressure, heart failure, or kidney disease.,This solution is given through a vein; you may feel warmth or discomfort at the injection site.,Follow your doctor's instructions regarding fluid intake and monitoring of blood sugar levels.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose provides caloric supplementation and serves as a source of glucose for cellular metabolism. Sodium chloride provides electrolytes for maintenance of fluid and electrolyte balance.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day, rate dependent on clinical condition and fluid status; maximum infusion rate usually 5 m L/kg/hour.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is classified as Category A/B. First trimester: No evidence of teratogenicity from dextrose or sodium chloride at recommended doses. Second and third trimesters: Use is generally safe; however, administration of. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.